Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Sumitomo Dainippon Pharma Co., Ltd.
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Co., Ltd.
ClinicalTrials.gov Identifier:
First received: June 6, 2012
Last updated: June 4, 2014
Last verified: June 2014

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Condition Intervention Phase
Drug: SM-13496
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

Resource links provided by NLM:

Further study details as provided by Sumitomo Dainippon Pharma Co., Ltd.:

Primary Outcome Measures:
  • Change from baseline in PANSS total score [ Time Frame: Change from baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 435
Study Start Date: August 2012
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SM-13496 Drug: SM-13496
40 or 80 mg once daily orally


Ages Eligible for Study:   18 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who are considered by the investigator eligible for the present study with no significant safety concerns
  • Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

  • Patients who are planning pregnancy for the expected duration of the study
  • Patients who are otherwise considered ineligible for the study by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01614912

Contact: Dainippon Sumitomo Pharma Co., Ltd. Japan cc@ds-pharma.co.jp

55 Sites Recruiting
Tokyo, etc, Japan
Principal Investigator: Doctor Site         
Korea, Republic of
14 Sites Recruiting
Seoul, etc, Korea, Republic of
Principal Investigator: Doctor Site         
8 Sites Recruiting
Kuala Lumpur, etc, Malaysia
Principal Investigator: Docter Site         
12Sites Recruiting
Taipei, etc, Taiwan
Principal Investigator: Doctor Site         
Sponsors and Collaborators
Sumitomo Dainippon Pharma Co., Ltd.
  More Information

No publications provided

Responsible Party: Sumitomo Dainippon Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT01614912     History of Changes
Other Study ID Numbers: D1001057
Study First Received: June 6, 2012
Last Updated: June 4, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on June 29, 2015